Daniel O’Day, the CEO of Gilead.

Ruben Sprich / Reuters

Gilead Sciences just announced plans for two late-stage clinical studies to test a treatment for COVID-19, the disease caused by the growing coronavirus outbreak. 

The studies will enroll approximately 1,000 patients with confirmed cases of COVID-19 across Asian countries and other areas with high rates of cases, the company said on Wednesday.

The two trials will test an antiviral medication called remdesivir, a therapy that was previously tested against the Ebola virus.

A Gilead executive said other studies of remdesivir in China would “give us a more expansive breadth of data globally on the drug’s profile in a short amount of time.”

Visit Business Insider’s homepage for more stories.

The $95 billion biotech Gilead Sciences is accelerating its effort to test a

Read More At Article Source | Article Attribution